The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
The role of alternative splicing in cancer: From oncogenesis to drug resistance
Open accessAbstract
Alternative splicing is a tightly regulated process whereby non-coding sequences of pre-mRNA are removed and protein-coding segments are assembled in diverse combinations, ultimately giving rise to proteins with distinct or even opposing functions. In the past decade, whole genome/transcriptome sequencing studies revealed the high complexity of splicing regulation, which occurs co-transcriptionally and is influenced by chromatin status and mRNA modifications. Consequently, splicing profiles of both healthy and malignant cells display high diversity and alternative splicing was shown to be widely deregulated in multiple cancer types. In particular, mutations in pre-mRNA regulatory sequences, splicing regulators and chromatin modifiers, as well as differential expression of splicing factors are important contributors to cancer pathogenesis. It has become clear that these aberrations contribute to many facets of cancer, including oncogenic transformation, cancer progression, response to anticancer drug treatment as well as resistance to therapy. In this respect, alternative splicing was shown to perturb the expression a broad spectrum of relevant genes involved in drug uptake/metabolism (i.e. SLC29A1, dCK, FPGS, and TP), activation of nuclear receptor pathways (i.e. GR, AR), regulation of apoptosis (i.e. MCL1, BCL-X, and FAS) and modulation of response to immunotherapy (CD19). Furthermore, aberrant splicing constitutes an important source of novel cancer biomarkers and the spliceosome machinery represents an attractive target for a novel and rapidly expanding class of therapeutic agents. Small molecule inhibitors targeting SF3B1 or splice factor kinases were highly cytotoxic against a wide range of cancer models, including drug-resistant cells. Importantly, these effects are enhanced in specific cancer subsets, such as splicing factor-mutated and c-MYC-driven tumors. Furthermore, pre-clinical studies report synergistic effects of spliceosome modulators in combination with conventional antitumor agents. These strategies based on the use of low dose splicing modulators could shift the therapeutic window towards decreased toxicity in healthy tissues. Here we provide an extensive overview of the latest findings in the field of regulation of splicing in cancer, including molecular mechanisms by which cancer cells harness alternative splicing to drive oncogenesis and evade anticancer drug treatment as well as splicing-based vulnerabilities that can provide novel treatment opportunities. Furthermore, we discuss current challenges arising from genome-wide detection and prediction methods of aberrant splicing, as well as unravelling functional relevance of the plethora of cancer-related splicing alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–239 of 239
Protein-Related Circular RNAs in Human Pathologies
Wawrzyniak, O., Zarębska, Ż., Kuczyński, K., Gotz‐Więckowska, A., & Rolle, K. (2020) · Cells · doi:10.3390/cells9081841 · Cited by 61
Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy
Dong, X., & Chen, R. (2019) · Oncogene · doi:10.1038/s41388-019-1138-2 · Cited by 59
Kfir‐Erenfeld, S., Sionov, R. V., Spokoini, R., Cohen, O., & Yefenof, E. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.506570 · Cited by 58
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma
Zhang, S., Wei, J. S., Li, S. Q., Badgett, T. C., Song, Y. K., Agarwal, S., Coarfa, C., Tolman, C., Hurd, L., Liao, H., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.11.045 · Cited by 58
Stark, M., Bram, E. E., Akerman, M., Mandel‐Gutfreund, Y., & Assaraf, Y. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163444 · Cited by 56
Self-citationVeuger, M. J. T., Heemskerk, M. H. M., Honders, M. W., Willemze, R., & Barge, R. M. Y. (2002) · Blood · doi:10.1182/blood.v99.4.1373 · Cited by 55
Selvanathan, S. P., Graham, G. T., Grego, A., Baker, T. M., Hogg, J. R., Simpson, M., Batish, M., Crompton, B. D., Stegmaier, K., Tomazou, E. M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz699 · Cited by 55
Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells
Tyson-Capper, A. J., & Gautrey, H. (2018) · RNA Biology · doi:10.1080/15476286.2018.1551692 · Cited by 54
Ajith, S., Gazzara, M. R., Cole, B. S., Shankarling, G. S., Martínez, N. M., Mallory, M. J., & Lynch, K. W. (2016) · RNA Biology · doi:10.1080/15476286.2016.1176663 · Cited by 53
DDX54 regulates transcriptome dynamics during DNA damage responsePreprint
Milek, M., Imami, K., Mukherjee, N., Bortoli, F. D., Zinnall, U., Hazapis, O. G., Trahan, C., Oeffinger, M., Heyd, F., Ohler, U., et al. (2017) · Genome Research · doi:10.1101/gr.218438.116 · Cited by 53
Wang, C., Sashida, G., Saraya, A., Ishiga, R., Koide, S., Oshima, M., Isono, K., Koseki, H., & Iwama, A. (2014) · Blood · doi:10.1182/blood-2013-12-544544 · Cited by 50
Alternative splicing: An important mechanism in stem cell biology
Chen, K., Dai, X., & Wu, J. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.1 · Cited by 50
Licatalosi, D. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-29073-7_6 · Cited by 49
Splicing controls the ubiquitin response during DNA double-strand break repair
Pederiva, C., Böhm, S., Julner, A., & Farnebo, M. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.58 · Cited by 46
Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells
Gao, Y., Trivedi, S., Ferris, R. L., & Koide, K. (2014) · Scientific Reports · doi:10.1038/srep06098 · Cited by 44
Aoki, S., Morita, M., Hirao, T., Yamaguchi, M., Shiratori, R., Kikuya, M., Chibana, H., & Ito, K. (2017) · Oncotarget · doi:10.18632/oncotarget.21689 · Cited by 44
DIFFUSE: predicting isoform functions from sequences and expression profiles via deep learning
Chen, H., Shaw, D., Zeng, J., Bu, D., & Jiang, T. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz367 · Cited by 44
Jang, Y., Elsayed, Z., Eki, R., He, S., Du, K., Abbas, T., & Kai, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913280117 · Cited by 43
Comparison of Alternative Splicing Junction Detection Tools Using RNASeq Data
Ding, L., Rath, E. C., & Bai, Y. (2017) · Current Genomics · doi:10.2174/1389202918666170215125048 · Cited by 42
Anufrieva, K. S., Shender, V. О., Arapidi, G. P., Pavlyukov, M. S., Shakhparonov, M. I., Shnaider, P. V., Butenko, I., Lagarkova, M. A., & Govorun, V. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0557-y · Cited by 40
Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify
Komor, M. A., Pham, T. V., Hiemstra, A. C., Piersma, S. R., Bolijn, A. S., Schelfhorst, T., Diemen, P. M. D., Tijssen, M., Sebra, R., Ashby, M., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir117.000056 · Cited by 39
Dissecting splicing decisions and cell-to-cell variability with designed sequence libraries
Mikl, M., Hamburg, A., Pilpel, Y., & Segal, E. (2019) · Nature Communications · doi:10.1038/s41467-019-12642-3 · Cited by 33
Yang, Y.-T., Chiu, Y.-C., Kao, C.-J., Hou, H.-A., Lin, C.-C., Tsai, C.-H., Tseng, M.-H., Chou, W.-C., & Tien, H.-F. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0115-2 · Cited by 32
Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies
Damm, F., Nguyen‐Khac, F., Fontenay, M., & Bernard, O. (2012) · Leukemia · doi:10.1038/leu.2012.86 · Cited by 32
Moore, A. S., Alonzo, T. A., Gerbing, R. B., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24822 · Cited by 30
Management of V600E and V600K BRAF-Mutant Melanoma
Haugh, A. M., & Johnson, D. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0680-z · Cited by 30
The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles
Meng, X., Yang, S., & Camp, V. J. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01538 · Cited by 30
Hu, Y., Wang, K., & Li, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007925 · Cited by 30
Gurskaya, N. G., Staroverov, D. B., Zhang, L., Fradkov, A. F., Markina, N. M., Pereverzev, A. P., & Lukyanov, K. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1314 · Cited by 29
The impact of biological sex on alternative splicingPreprint
Karlebach, G., Veiga, D. F. T., Mays, A. D., Chatzipantsiou, C., Barja, P. P., Chatzou, M., Kesarwani, A. K., Daniš, D., Kararigas, G., Zhang, X., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/490904 · Cited by 28
Bao, S., Moakley, D. F., & Zhang, C.-L. (2019) · Cell · doi:10.1016/j.cell.2019.01.013 · Cited by 28
Multiple roles of the splicing complex SF3B in DNA end resection and homologous recombination
Prados‐Carvajal, R., López-Saavedra, A., Cepeda-García, C., Jimeno, S., & Huertas, P. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.04.003 · Cited by 27
Zheng, X. Y., Zhan, Z., Naren, D., Li, J., Yan, T., & Gong, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185053 · Cited by 26
Leivonen, S., Taskinen, M., Cervera, A., Karjalainen‐Lindsberg, M., Delabie, J., Holte, H., Lehtonen, R., Hautaniemi, S., & Leppä, S. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.71 · Cited by 23
Depletion of the MFAP1/SPP381 Splicing Factor Causes R-Loop-Independent Genome Instability
Salas‐Armenteros, I., Barroso, S. I., Rondón, A. G., Pérez-Alegre, M., Andújar, E., Luna, R., & Aguilera, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.010 · Cited by 22
Sciarrillo, R., Wojtuszkiewicz, A., Kooi, I. E., León, L. G., Sonneveld, E., Kuiper, R. P., Jansen, G., Giovannetti, E., Kaspers, G. J. L., & Cloos, J. J. (2020) · Cancers · doi:10.3390/cancers12030723 · Cited by 21
Self-citationEffects of DNA topoisomerase IIα splice variants on acquired drug resistance
Elton, T. S., Özer, H. G., & Yalowich, J. C. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.117 · Cited by 17
Zhang, J., Wang, Y., Li, S., Fang, L., Wang, X., Li, J., Zhang, H., Huang, B., Xu, Y., Yang, W., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16472 · Cited by 15
Survey of Programs Used to Detect Alternative Splicing Isoforms from Deep Sequencing DataIn Silico
Min, F., Wang, S., & Zhang, L. (2015) · BioMed Research International · doi:10.1155/2015/831352 · Cited by 9
Cited by
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Deguchi, Y., Kikutake, C., & Suyama, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-65035-y · Cited by 5
Metadata
- Authors
- Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 53
- Pages
- 100728
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3091597462
- Cited by
- 307
- References
- 239
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.